TIDMSNG
RNS Number : 0808B
Synairgen plc
29 September 2022
Synairgen plc
('Synairgen' or the 'Company')
Board Changes
Southampton, UK - 29 September 2022: Synairgen plc (LSE: SNG),
the respiratory company developing SNG001, an investigational
formulation for inhalation containing the broad-spectrum antiviral
protein interferon beta, today announces the appointment of Dr
Felicity ('Flic') Gabbay to the Board as a Non-Executive
Director.
Simultaneous to this announcement, Theodora Harold is stepping
down from the Board with immediate effect.
Flic has extensive experience within the life sciences sector
including holding several senior and CEO positions in big pharma,
biotech and CROs in both Europe and North America. As Founder and
Managing Partner at TranScrip LLP, founded in 2008, she has
overseen drug development work with companies at all stages of the
drug development cycle, as well as securing private equity
investment and the acquisition of Real Regulatory.
Starting her career as a medical doctor, Flic held various
medical posts across Europe before moving into the biotechnology
sector. She is the current President of the Faculty of
Pharmaceutical Medicine for the three Royal Colleges of
Physicians.
In 2020, Flic was awarded the Fellowship of the Academy of
Medical Science and is passionate about bringing pharmaceutical
medicine into mainstream medical science and its application to
public health.
She completed a BSc in Pharmacology and a Bachelor of Medicine
and Surgery degree at the University of Manchester.
In the ordinary course of business, Synairgen contracts
outsourced medical affairs and clinical development services from
TranScrip, which are conducted on an "arm's length" basis. The
Board is satisfied that the provision of services by TranScrip does
not impact on Flic's independence as a non-executive director.
Simon Shaw, Chair of Synairgen, said : "Flic is highly
experienced with a deep understanding of drug development and
pharmaceutical medicine. Over her distinguished career, she has
gained invaluable experience in supporting companies to progress
their candidate drugs through the clinic and we look forward to
benefitting from her insights as we continue the clinical
development of SNG001. I wish to thank Theo for her contributions
during the period of her service and wish her well with her future
endeavours."
Flic Gabbay commented : "I am pleased to join the Board of
Synairgen as it works towards the next milestones for SNG001 as a
potential therapeutic for severe respiratory viral infections. I
look forward to working closely with the Synairgen Management team
and Board on the next steps for the Company's clinical
development."
Relevant disclosures
The following disclosures are required under Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Mrs Felicity Jane Gabbay, aged 70, has held no previous
directorships and/or partnerships in the past five years, but
currently holds the following directorships:
Current directorships:
-- Transcrip Limited
-- Project Altair Midco Limited
-- Project Altair Holdco Limited
-- Transcrip Partners International Limited
-- Transcrip Partners LLP
-- The Faculty of Pharmaceutical Medicine of the Royal Colleges
of Physicians of the United Kingdom
Felicity does not have any beneficial interest in the ordinary
shares of the Company.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No. 596/2014 ('MAR').
For further enquiries, please contact:
Synairgen plc
Brooke Clarke, Head of Communications
Media@synairgen.com
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Charlie Beeson (Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Namrata Taak, Lucy Featherstone
cscsynairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of severe viral lung infections, including COVID-19, as
potentially the first host-targeted, broad-spectrum antiviral
treatment delivered directly into the lungs. SNG001 has been
granted Fast Track status from the US Food and Drug Administration
(FDA). Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADGGDCUSDDGDI
(END) Dow Jones Newswires
September 29, 2022 02:01 ET (06:01 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
